newsfilter
← Latest News
GlobeNewswire·

MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights

Enrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway 12-week MAD (Part C, Cohort 1) data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity designed for once-monthly dosing, on track